Publications by authors named "Rebeca Alcala-Garcia"
Background: We assessed pain, acceptability, patient preference, and tolerability of patients with psoriasis and psoriatic arthritis after switching guselkumab from a prefilled syringe to One-Press autoinjector pen.
Methods: Patients with psoriasis and psoriatic arthritis treated for at least 6 months with guselkumab syringe were recruited from January 2019 to December 2022. Gender, age, diagnosis, self-administration and pain perception of guselkumab prefilled syringe were recorded.
Background: We assessed pain, acceptability, patient preference, and tolerability of patients with psoriasis and psoriatic arthritis after switching guselkumab from a prefilled syringe to One-Press autoinjector pen.
Methods: Patients with psoriasis and psoriatic arthritis treated for at least 6 months with guselkumab syringe were recruited from Jan 2019 to Dec 2022. Gender, age, diagnosis, self-administration, and pain perception of guselkumab prefilled syringe were recorded.
Article Synopsis
- The research evaluates the effectiveness and safety of bimekizumab for treating hidradenitis suppurativa in real-world clinical settings.
- Significant improvements were observed in key activity scores and patient-reported outcomes after 16 weeks, with all results showing a strong statistical significance (p < 0.001).
- Bimekizumab was well-tolerated with no reported discontinuations or new safety issues, reaffirming its favorable safety profile previously seen in phase 3 clinical trials.